JP2023532415A - 改変セマフォリン３ａ、それを含む組成物およびその使用 - Google Patents

改変セマフォリン３ａ、それを含む組成物およびその使用 Download PDF

Info

Publication number
JP2023532415A
JP2023532415A JP2022574527A JP2022574527A JP2023532415A JP 2023532415 A JP2023532415 A JP 2023532415A JP 2022574527 A JP2022574527 A JP 2022574527A JP 2022574527 A JP2022574527 A JP 2022574527A JP 2023532415 A JP2023532415 A JP 2023532415A
Authority
JP
Japan
Prior art keywords
sema3a
modified
polypeptide
semaphorin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532415A5 (https=
Inventor
ザハバ バダッツ、
トービ、エリアス
ナスレン エイザ、
アディ サバグ、
ゲラ ニューフェルド、
オフラ ケスラー、
イー． イボンヌ ヨネス、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Original Assignee
Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research & Development Fund for Health Services Bnai Zion Medical Center filed Critical Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Publication of JP2023532415A publication Critical patent/JP2023532415A/ja
Publication of JP2023532415A5 publication Critical patent/JP2023532415A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022574527A 2020-06-04 2021-06-03 改変セマフォリン３ａ、それを含む組成物およびその使用 Pending JP2023532415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034476P 2020-06-04 2020-06-04
US63/034,476 2020-06-04
PCT/IL2021/050660 WO2021245670A1 (en) 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof

Publications (2)

Publication Number Publication Date
JP2023532415A true JP2023532415A (ja) 2023-07-28
JP2023532415A5 JP2023532415A5 (https=) 2024-04-09

Family

ID=78830160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574527A Pending JP2023532415A (ja) 2020-06-04 2021-06-03 改変セマフォリン３ａ、それを含む組成物およびその使用

Country Status (8)

Country Link
US (1) US20230272020A1 (https=)
EP (1) EP4161659A4 (https=)
JP (1) JP2023532415A (https=)
CN (1) CN115916351A (https=)
AU (1) AU2021284697A1 (https=)
CA (1) CA3185618A1 (https=)
IL (1) IL298678A (https=)
WO (1) WO2021245670A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947817B (zh) * 2023-02-22 2024-07-02 甘肃中肽生物科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160129079A1 (en) * 2013-06-13 2016-05-12 Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center Semaphorin 3a for treatment and prognosis of systemic lupus erythematosus
JP2018506994A (ja) * 2015-02-23 2018-03-15 シーガル セラピューティクス エスアーエス 非天然セマフォリン３およびそれらの医学的使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160129079A1 (en) * 2013-06-13 2016-05-12 Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center Semaphorin 3a for treatment and prognosis of systemic lupus erythematosus
US10105413B2 (en) * 2013-06-13 2018-10-23 Medical Research & Development Fund for Health Services Bnai Zion Medical Center Semaphorin 3A for treatment of systemic lupus erythematosus
JP2018506994A (ja) * 2015-02-23 2018-03-15 シーガル セラピューティクス エスアーエス 非天然セマフォリン３およびそれらの医学的使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENOME BIOLOGY, vol. 7:211, JPN6025022116, 2006, ISSN: 0005609078 *
J. MOL. BIOL., vol. 425(22), JPN6025022118, 2013, pages 4405 - 4414, ISSN: 0005609077 *

Also Published As

Publication number Publication date
WO2021245670A1 (en) 2021-12-09
IL298678A (en) 2023-01-01
AU2021284697A1 (en) 2023-01-19
CA3185618A1 (en) 2021-12-09
US20230272020A1 (en) 2023-08-31
CN115916351A (zh) 2023-04-04
EP4161659A4 (en) 2024-03-06
EP4161659A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
CN108004259B (zh) 靶向b细胞成熟抗原的嵌合抗原受体及其用途
KR20180131545A (ko) 트랜스포존 시스템 및 사용 방법
KR101985271B1 (ko) Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도
KR20210043623A (ko) Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
WO2020245343A1 (en) Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
EP4310188A1 (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
JP2026035742A (ja) 生体高分子標的特異的補体阻害剤及びその製造方法と応用
JP7432250B2 (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
EP3570852A1 (en) Methods of treating multiple sclerosis using autologous t cells
CN113195528A (zh) 对ha-1h特异的结合蛋白及其用途
KR20220044683A (ko) 관절염 치료를 위한 hla-dr/cii 펩티드 복합체
CN102030822A (zh) 人类新细胞因子VSTM1-v2及其应用
JP2023532415A (ja) 改変セマフォリン３ａ、それを含む組成物およびその使用
US20260042815A1 (en) Universal t cells and compositions and methods of use thereof
CN114702596B (zh) 靶向人cd33和nkg2dl的嵌合抗原受体细胞及其制备方法和应用
CN118221829A (zh) 一种il-10单体融合蛋白
CN117083384A (zh) 工程细胞的基因转移载体和方法
AU2021219886A1 (en) Optimization of chimeric antigen receptor
CN115867584A (zh) 用于减少嵌合抗原受体强直信号传导的方法和组合物
EP4538285A1 (en) Pd-1 variant and use thereof
HK40103877A (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
HK40126591A (zh) 通用t细胞和组合物及它们的使用方法
WO2024050551A2 (en) Compositions and methods for in vivo expression of chimeric antigen receptors
WO2024141788A1 (en) Genetically modified stem cells expressing exogenous binding agents and uses thereof
CN118995620A (zh) 一种嵌合抗原受体、重组免疫细胞及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202